Literature DB >> 6165742

Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects.

J J Vallner, J T Stewart, J A Kotzan, E B Kirsten, I L Honigberg.   

Abstract

In a relatively small pilot study, the half-life of elimination of hydromorphone in six subjects was 2.64 +/- 0.88 hours and the drug had a high volume of distribution, 1.22 l./kg. In addition, the drug was rapidly but incompletely absorbed after oral administration. An equation to predict the plasma concentration of hydromorphone on oral administration was developed from the data of these six subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165742     DOI: 10.1002/j.1552-4604.1981.tb05693.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  18 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

2.  Effect of ethanol on opioid drug permeability through caco-2 cell monolayers.

Authors:  Donna A Volpe; Ebenezer B Asafu-Adjaye; Christopher D Ellison; Suresh Doddapaneni; Ramana S Uppoor; Mansoor A Khan
Journal:  AAPS J       Date:  2008-07-01       Impact factor: 4.009

Review 3.  OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 4.  Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients.

Authors:  Michael A Smith; Maho Hibino; Bonnie A Falcione; Katherine M Eichinger; Ravi Patel; Kerry M Empey
Journal:  Ann Pharmacother       Date:  2013-11-04       Impact factor: 3.154

Review 5.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

7.  Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Authors:  George A Davis; Anita C Rudy; Sanford M Archer; Daniel P Wermeling; Patrick J McNamara
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

Review 9.  Hydromorphone Prescription for Pain in Children-What Place in Clinical Practice?

Authors:  Frédérique Rodieux; Anton Ivanyuk; Marie Besson; Jules Desmeules; Caroline F Samer
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

10.  Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers.

Authors:  Terhi J Lohela; Satu Poikola; Mikko Neuvonen; Mikko Niemi; Janne T Backman; Klaus T Olkkola; Tuomas O Lilius
Journal:  Anesth Analg       Date:  2021-08-01       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.